ECMO Use in Pediatric Oncology and HSCT Patients: A Descriptive and Comparative Analysis

July 15, 2026 updated by: Michelle Brown, Children's Mercy Hospital Kansas City
This was an observational study, with a descriptive and comparative portion. The descriptive analysis, a large single center experience, examined bleeding complications, infectious rates, and survival outcomes in patients under 18 years old with an underlying oncologic diagnosis and/or hematopoietic stem cell transplant on Extracorporeal membrane oxygenation (ECMO). In a small multicenter cohort, the comparative analysis evaluated survival outcomes in this population with respiratory failure in the presence and absence of ECMO. Children's Mercy Kansas City served as the ECMO cohort; Cincinnati Children's Hospital Medical Center served as the matched non-ECMO cohort.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

22

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Pediatric patients, under the age of 18, admitted to a tertiary care pediatric intensive care unit for management of respiratory failure warranting mechanical ventilation. Beyond this, only pediatric patients with an underlying oncologic and/or hematopoietic stem cell transplant were included in the study.

Description

Inclusion Criteria:

  • Less than 18 years old
  • Admitted to the PICU for respiratory failure (2015-2023)
  • Underlying oncologic diagnosis and/or hematopoietic stem cell transplant
  • Mechanical ventilation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
ECMO Cohort
Eleven patients under 18 years old with an underlying oncologic diagnosis and/or hematopoietic stem cell transplant received Extracorporeal membrane oxygenation (ECMO) as a rescue therapy for respiratory failure. Children's Mercy Hospital served as the ECMO cohort.
Other: Extracorporeal membrane oxygenation (ECMO)
ECMO utilization in patient with malignancy and/or history of hematopoietic stem cell transplant.
Non-ECMO Cohort
Eleven patients under 18 years old with an underlying oncologic diagnosis and/or hematopoietic stem cell transplant received conventional therapies for management of respiratory failure. Cincinnati Children's Hospital Medical Center served as the non-ECMO cohort.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Comparison of survival rates in pediatric patients with an underlying malignancy and/ or hematopoietic stem cell transplant in the presence and absence of ECMO support
Time Frame: Admission until hospital discharge, average of 46 days
Admission until hospital discharge, average of 46 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Children's Mercy Hospital Kansas City

Collaborators

Children's Hospital Medical Center, Cincinnati

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2015

Primary Completion (Actual)

December 1, 2024

Study Completion (Actual)

April 1, 2025

Study Registration Dates

First Submitted

July 10, 2026

First Submitted That Met QC Criteria

July 15, 2026

First Posted (Actual)

July 20, 2026

Study Record Updates

Last Update Posted (Actual)

July 20, 2026

Last Update Submitted That Met QC Criteria

July 15, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • STUDY00001444

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Solid Tumor Malignancies

Clinical Trials on Extracorporeal membrane oxygenation (ECMO)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe